Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0V7HI
|
||||
| Former ID |
DIB007048
|
||||
| Drug Name |
PRINOMIDE TROMETHAMINE
|
||||
| Synonyms |
3-(1-Methylpyrrol-2-yl)-3-oxo-2-(N-phenylcarbamoyl)propionitrile tromethamine salt
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Inflammation [ICD10:E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89] | Discontinued in Phase 3 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H24N4O5
|
||||
| Canonical SMILES |
Cn1cccc1C(=O)C(C#N)C(=O)Nc2ccccc2.NC(CO)(CO)CO
|
||||
| InChI |
1S/C15H13N3O2.C4H11NO3/c1-18-9-5-8-13(18)14(19)12(10-16)15(20)17-11-6-3-2-4-7-11;5-4(1-6,2-7)3-8/h2-9,12H,1H3,(H,17,20);6-8H,1-3,5H2
|
||||
| InChIKey |
CPUJDORGQAJDCT-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 109636-76-2
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Prostaglandin G/H synthase 2 | Target Info | Inhibitor | [2], [3] | |
| BioCyc Pathway | Aspirin-triggered lipoxin biosynthesis | ||||
| Aspirin triggered resolvin D biosynthesis | |||||
| C20 prostanoid biosynthesis | |||||
| Aspirin triggered resolvin E biosynthesis | |||||
| KEGG Pathway | Arachidonic acid metabolism | ||||
| Metabolic pathways | |||||
| NF-kappa B signaling pathway | |||||
| VEGF signaling pathway | |||||
| TNF signaling pathway | |||||
| Retrograde endocannabinoid signaling | |||||
| Serotonergic synapse | |||||
| Ovarian steroidogenesis | |||||
| Oxytocin signaling pathway | |||||
| Regulation of lipolysis in adipocytes | |||||
| Leishmaniasis | |||||
| Pathways in cancer | |||||
| Chemical carcinogenesis | |||||
| MicroRNAs in cancer | |||||
| Small cell lung cancer | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| TSH Signaling Pathway | |||||
| IL4 Signaling Pathway | |||||
| TGF_beta_Receptor Signaling Pathway | |||||
| IL5 Signaling Pathway | |||||
| PANTHER Pathway | Endothelin signaling pathway | ||||
| Inflammation mediated by chemokine and cytokine signaling pathway | |||||
| Toll receptor signaling pathway | |||||
| CCKR signaling map ST | |||||
| Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | ||||
| S1P1 pathway | |||||
| C-MYB transcription factor network | |||||
| Signaling mediated by p38-alpha and p38-beta | |||||
| Calcium signaling in the CD4+ TCR pathway | |||||
| PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | ||||
| Arachidonic acid metabolism | |||||
| Aryl Hydrocarbon Receptor | |||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||||
| Spinal Cord Injury | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Eicosanoid Synthesis | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000017) | ||||
| REF 2 | Dexketoprofene, selective cox-1 inhibitor nsaids, without gastrointestinal injury in rats. Acta Gastroenterol Latinoam. 2002 May;32(1):17-20. | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.